All In MedTech

Device Trial Radar · NCT07260474

Comparison of the Amplatzer Amulet Versus LAmbre Device for Left Atrial Appendage Closure

Comparison of the Amplatzer Amulet Versus LAmbre Device for Left Atrial Appendage Closure: the CALAMBRE Randomized Clinical Trial

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

May 5, 2024

Primary completion

Dec 31, 2026

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Fundación EPICAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 3, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical investigation with CE-marked medical devices, multicenter, prospective, randomized and controlled. Patients with non-valvular atrial fibrillation at high embolic risk and with at least one high bleeding risk criterion according to the Munich consensus document will be randomized to left atrial appendage closure with either the Amplatzer Amulet™ or the LAmbre™ device. The study is designed to compare the efficacy and safety of both devices regarding successful implantation, effective appendage closure, and clinical outcomes at follow-up.

Conditions

  • Coronary Artery Disease

Interventions

  • Patients implanted with Amplatzer Amulet™Device

    Left atrial appendage closure with the Amplatzer Amulet™ device. The procedure will be performed according to standard practice using the manufacturer's instructions for use.

  • Patients implanted with LAmbre™Device

    Left atrial appendage closure with the LAmbre™ device. The procedure will be performed according to standard practice using the manufacturer's instructions for use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EFFICACY: Device successTime frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario La Paz

    Fuencarral-El Pardo, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.